Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma
New Jersey-Based Slayback Founded A Decade Ago; Received KKR, Everstone Investments
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.
You may also be interested in...
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Slayback Pharma has now launched its Merzee generic version of Allergan’s Taytulla oral contraceptive with a CGT designation, several months after Xiromed moved first.